Physician profile
William C Pace
NPI 1114188893
$471,688.19
in general payments reported to CMS, 2019-2025
24 companies · $71K in 2025
The $71K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $30K · 2021: $75K · 2022: $96K · 2023: $73K · 2024: $108K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $228K · Travel and Lodging: $12K · Food and Beverage: $7,222 · Consulting Fee: $5,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $227,785.00 |
| Travel and Lodging | $12,187.65 |
| Food and Beverage | $7,221.96 |
| Consulting Fee | $5,925.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $417,270.10 | 2019-2025 | |
| Allergan, INC. | $48,922.83 | 2019-2021 | |
| Smith+Nephew, INC. | $1,029.84 | 2019-2025 | Collagenase Santyl, Grafix Pl, Allevyn Life L 15.4x15.4 Ctn10 |
| Melinta Therapeutics, LLC | $897.72 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $623.27 | 2020-2025 | Nuzyra |
| Organogenesis INC. | $600.69 | 2019-2024 | |
| Insmed, INC. | $520.06 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $309.93 | 2019-2023 | Prezcobix |
| Viiv Healthcare Company | $266.30 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Merck Sharp & Dohme LLC | $262.25 | 2019-2025 | Dificid, Delstrigo, Pifeltro |
| Gilead Sciences, INC. | $223.64 | 2019-2025 | Biktarvy |
| Janssen Pharmaceuticals, INC | $217.87 | 2019-2020 | |
| Integra Lifesciences Corporation | $132.94 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $104.12 | 2019-2025 | Vibativ |
| Janssen Products, Lp | $72.00 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $55.95 | 2019 | |
| Lifenet Health | $29.85 | 2024 | Theragenesis Wound Matrix |
| Kci USA, INC. | $29.69 | 2023 | Activ.A.C., Promogran Prisma |
| Astellas Pharma US INC | $29.15 | 2019 | |
| Medline Industries Lp | $22.00 | 2019 | |
| Kerecis Limited | $21.27 | 2022 | |
| Vyera Pharmaceuticals, LLC | $17.12 | 2019 | |
| Glaxosmithkline, LLC. | $15.83 | 2019 | |
| Theratechnologies INC. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.